Business Context and Reporting Period
The provided filing is Aeglea BioTherapeutics, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2019, filed August 6, 2019. The request metadata identifies Spyre Therapeutics, Inc.; the filing text itself does not identify Spyre and should be verified against the intended issuer.
Aeglea was a clinical-stage biotechnology company developing engineered human enzymes for diseases with unmet medical needs. Its lead candidate, pegzilarginase, was being evaluated in a global Phase 3 trial for Arginase 1 Deficiency, with additional development programs for Homocystinuria and Cystinuria. The company had no approved products and had not generated product revenue.
Financial Condition and Results
| Metric | Three months ended June 30, 2019 | Three months ended June 30, 2018 | Six months ended June 30, 2019 | Six months ended June 30, 2018 |
|---|---|---|---|---|
| Grant revenue | $0 | $2.4 million | $0 | $3.9 million |
| Research and development expense | $14.8 million | $9.1 million | $29.2 million | $16.0 million |
| General and administrative expense | $3.8 million | $2.9 million | $7.1 million | $5.8 million |
| Total operating expenses | $18.6 million | $12.0 million | $36.3 million | $21.8 million |
| Net loss | $18.0 million | $9.4 million | $35.2 million | $17.5 million |
| Net loss per share | $0.55 | $0.46 | $1.14 | $0.94 |
Operating margins are not meaningful because the company had no revenue in 2019. Six-month research and development expense increased 83%, primarily from Phase 3 and other clinical activities, expanded personnel, manufacturing investment and pre-commercial preparation. Six-month general and administrative expense increased 22%, principally from additional headcount and compensation.
- Cash and cash equivalents were $25.4 million at June 30, 2019, compared with $22.5 million at December 31, 2018.
- Marketable securities were $80.1 million, versus $52.1 million at year-end 2018.
- Cash, cash equivalents, marketable securities and restricted cash totaled $107.0 million at June 30, 2019.
- Working capital was $96.9 million and accumulated deficit was $152.0 million.
- Total liabilities were $17.9 million, including $5.1 million of operating and finance lease liabilities. The company reported no debt or credit facility.
- Six-month operating cash use was $32.2 million, compared with $16.5 million in the prior-year period.
- Six-month investing cash use was $28.1 million, primarily reflecting purchases of marketable securities.
- Six-month financing cash inflow was $64.7 million, primarily from the February 2019 equity and pre-funded warrant offering.
- Cash, cash equivalents and restricted cash increased by $4.5 million to $26.9 million at June 30, 2019.
Material Changes Versus the Prior Comparable Period
- Grant revenue ended because the $19.8 million CPRIT grant contract expired in May 2018; no grant revenue was recognized in 2019.
- Six-month net loss approximately doubled, increasing by $17.7 million, or 101%.
- Research and development expense increased by $13.2 million, driven by the Phase 3 PEACE trial, the Phase 2 extension study, oncology development, manufacturing and personnel.
- The company raised approximately $64.5 million of net proceeds in February 2019 through the sale of common stock and pre-funded warrants. Shares issued and outstanding increased from approximately 24.1 million at December 31, 2018 to 28.8 million at June 30, 2019; the pre-funded warrants had not been exercised.
- The company adopted ASC Topic 842 lease accounting on January 1, 2019, recording operating lease right-of-use assets and lease liabilities.
- In April 2019, the company entered into a lease for approximately 30,000 square feet of headquarters and laboratory space through April 2028 and posted $1.5 million of restricted cash as collateral.
Guidance, Outlook, Risks and Unusual Items
Management stated that existing cash, cash equivalents and marketable securities were expected to fund operations through the first quarter of 2021, based on current plans. Management also stated that additional financing would be required to complete all planned research and development activities. The filing provides no formal revenue or earnings guidance.
- The first patient had been dosed in the global Phase 3 PEACE trial in June 2019. Management expected topline data in the first quarter of 2021.
- Management expected to file an IND or CTA for AEB4104 in the first quarter of 2020 and continue IND-enabling work for AEB5100.
- The filing discusses post-quarter developments, including FDA Breakthrough Therapy Designation for pegzilarginase announced in July 2019 and interim oncology data announced in August 2019. These events were not part of the June 30, 2019 financial statements.
- Management expects operating losses and research and development spending to increase for the foreseeable future.
- Key risks include failure or delay of clinical trials, limited patient populations and enrollment challenges, regulatory uncertainty, adverse events, manufacturing and third-party dependence, intellectual-property disputes, competition, reimbursement uncertainty and the need for additional capital.
- The company had license obligations to the University of Texas at Austin, including up to $6.4 million of development milestone payments and low-single-digit royalties on net sales, plus potential revenue-sharing obligations on sublicense consideration.
- Contractual lease payments totaled approximately $9.5 million for operating leases and $0.1 million for finance leases before imputed interest and other adjustments.
- Management reported no material pending legal proceedings, no off-balance-sheet arrangements and effective disclosure controls at June 30, 2019.
Important Facts for Investors to Verify
- Confirm that the filing belongs to the intended company: the source names Aeglea BioTherapeutics, Inc., not Spyre Therapeutics, Inc.
- Verify the current corporate name, ticker, share count and any subsequent corporate transactions or name changes.
- Assess whether the projected cash runway through the first quarter of 2021 remains valid after actual clinical, manufacturing and administrative spending.
- Review the Phase 3 PEACE trial enrollment, endpoint design, topline timing and any subsequent regulatory or clinical updates.
- Quantify potential dilution from the 4.0 million pre-funded warrants, the $60.0 million at-the-market program and the $200.0 million shelf registration.
- Evaluate clinical safety signals, manufacturing readiness, third-party dependencies and the status of University of Texas license obligations.